FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
07/23/2026
Back to search
Official data from USPTO
AB ANALITICA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
AB ANALITICA
ST13
US500000079399168Class
5, 42
Filing
79399168
Registration
8054659
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
33
Latest update
07/23/2026
Trademark type
Word
Nice classes
5, 42
Filing date
03/21/2024
Registration date
12/09/2025
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
12/09/2025
Last transaction
07/23/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
99
Owner location
IT
Examiner
LOBO, DEBORAH E
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
AB ANALITICA S.r.l.
Representatives
Robert S. Broder Collard & Roe, P.C.
Technical classification
Nice Classes
Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Gastrointestinal treatment preparations; medicines for the treatment of gastrointestinal diseases; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; milk sugar for pharmaceutical purposes; vaccines; diagnostic preparations for medical purposes; diagnostic preparations and substances for medical purposes; clinical medical reagents; clinical diagnostic reagents for medical use; diagnostic agents for medical use; diagnostic substances for medical use; diagnostic agents for pharmaceutical use; biological indicators for medical diagnosis; pregnancy testing preparations; in vitro diagnostic preparations for medical use; chemical reagents for in-vitro veterinary purposes for use by veterinary laboratories; chemical reagents for in-vitro medical purposes for use by medical laboratories; pharmaceutical preparations and substances for the prevention of cancer; pharmaceutical preparations and substances for the treatment of cancer; pharmaceutical compounds for treating cancer; male fertility test kits; reagents for medical use; diagnostic reagents for medical use; biological reagents for medical use; chemical reagents for medical use; reagents for use with analyzers for medical purposes; diagnostic chemical reagents for medical use; reagents for use in analysis for medical purposes; chemical test reagents for medical purposes; diagnostic biomarker reagents for medical purposes; reagents for use in diagnostic tests for medical purposes; reagents for microbiological analysis for medical purposes; chemical reagents for medical or veterinary purposes; reagents for use in medical genetic testing; reagents for use in diagnostic tests for veterinary purposes; reagents for analytical purposes for medical purposes; medical diagnostic reagents and assays for testing of body fluids; reagents for use in diagnostic pregnancy tests; reagents for use in analysis for veterinary purposes; culture media for medical use; reagents for use in veterinary genetic testing; biochemical preparations for medical use; preparations for detecting mutation in prion genes for medical purposes; preparations for detecting genetic predispositions for medical purposes; glucose for medical purposes; glucose dietary supplements; glucose for use as an additive to foods for medical purposes; pharmaceutical preparations for the prevention of disorders of the metabolic system; pharmaceutical preparations for treating metabolic disorders; pharmaceutical preparations for treating gastrointestinal disorders; antivirals in the nature of DNA synthesis inhibitors; chemical preparations for use in DNA analysis for medical purposes; dietary supplements and dietetic preparations; diagnostic preparations for medical or veterinary purposes.
Class 42
Pharmaceutical drug development services; research on the subject of pharmaceuticals; scientific research in the field of pharmacy; medical and pharmacological research services; medical research laboratory services; testing of pharmaceuticals; research and development of vaccines and medicines; design and development of medical diagnostic apparatus; scientific research for medical purposes in the area of cancerous diseases; research and development in the field of diagnostic preparations; genetic research; scientific research in the field of genetics and genetic engineering; scientific research relating to genetics; laboratory research in the field of gene expression; DNA screening for scientific research purposes; laboratory research servicesDNA testing services to determine paternity; testing for new product development; design and testing for new product development; testing of new product designs for others; new product design; quality control for others; design and testing for new product development; design and testing of new products; scientific research and development; pharmaceutical research and development; research and development in the pharmaceutical and biotechnology fields; scientific research and development services; research and development of computer software; development and testing of chemical production methods; quality control of manufactured goods; design and development of computer hardware; software design and development; design of instruments; design services relating to data processing tools; design and development of diagnostic apparatus; product research and development; computer design research; development of pharmaceutical preparations and medicines; scientific investigations for medical purposes; biological researchclinical research and medical research; research in the field of pharmacogenetics; laboratory testing of materials; laboratory services for medical research; research and development in the field of microorganisms and cells; research relating to molecular sciences; research and development in the field of biotechnology; bacteriological research; toxicology testing for research purposes; biological research and analysis; physics research; chemical research; scientific research relating to biology; biological research laboratory services; research and development services in the field of immunohistology; provision of medical research services; leasing of scientific laboratory research instruments; computer rental; software developmentprogramming and implementation; data mining; computer software design and updating; preparation of technical reports in the pharmaceutical field; preparation of scientific reports in the pharmaceutical field; technological research in the pharmaceutical field; scientific analysis in the field of molecular biology; biological research.
Publications
History of USPTO decisions and trademark events.
33 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
07/03/2026
FIMP
FINAL DISPOSITION PROCESSED
07/03/2026
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
03/09/2026
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
12/18/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
12/09/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
12/09/2025
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
12/03/2025
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
12/03/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
10/21/2025
PUBO
PUBLISHED FOR OPPOSITION
10/21/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
10/15/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
09/22/2025
XAEC
EXAMINER'S AMENDMENT ENTERED
09/22/2025
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
09/22/2025
GNEA
EXAMINERS AMENDMENT E-MAILED
09/22/2025
CNEA
EXAMINERS AMENDMENT -WRITTEN
09/22/2025
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
03/09/2025
GNRT
NON-FINAL ACTION E-MAILED
03/09/2025
CNRT
NON-FINAL ACTION WRITTEN
03/09/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/05/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/05/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
02/05/2025
RFNT
REFUSAL PROCESSED BY IB
11/02/2024
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
10/11/2024
RFRR
REFUSAL PROCESSED BY MPU
10/11/2024
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
10/09/2024
CNRT
NON-FINAL ACTION WRITTEN
10/08/2024
DOCK
ASSIGNED TO EXAMINER
09/28/2024
MAFR
APPLICATION FILING RECEIPT MAILED
07/12/2024
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
07/12/2024
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
07/08/2024
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
07/04/2024
Continuous trademark protection
Get notified about every new filing that threatens AB ANALITICA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.